Modern Biopharmaceuticals

Dr. Jörg Knäblein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).
 
AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.
 
With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

Due to the impressive accumulation of out-standing results, presented by brilliant, privileged and creative thinkers, this unique book reads like the 'Who is Who' of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R.

Volume 1
 
INTRODUCTION
PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE
Genes & genomes - correlation between genes, diseases & biopharmaceuticals
siRNA - the magic bullet & other gene therapeutical approaches
Mobilis in mobile - human embryonic stem cells & other sources for cell therapy
 

Volume 2
 
PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION
The clotting cascade - lysis, coagulation & a fine-tuned balance
Errare humanum est - what causes cancer & how to selectively fight tumors
Mundus vult decipi - high mutation rates of HIV & new paradigms for treatment
PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS
Citius, altius, fortius - acceleration by high throughput & ultra-HT
Early target validation - knock-out mice & more
Revolution by evolution - rational design for desire & the scientific art of optimization
 

Volume 3
 
PART IV: PRODUCTION OF BIOPHARMACEUTICALS
The industry's workhorses - mammalian expression systems
A ripe and blooming market - biopharmaceuticals from transgenic animals & plants
Alea non iacta est - improving established expression systems
When success raises its ugly head - outsourcing to uncork the capacity bottleneck
PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING
From hunter to craftsman - engineering antibodies with nature's universal toolbox
Find, fight & follow - target-specific troica from Mother Nature's Pharmacopoiea
Getting insight - sense the urgency for early diagnostics
 

Volume 4
 
PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS
Getting inside - quest for the best & how to improve delivery
Pathfinder - new ways for peptides, proteins & Co
Via mala - the stony road of DNA delivery: back-pack, feed-back & pay-back
Getting beyond - rocket science & science fiction
PART VII: FROM TRANSCRIPTION TO PRESCRIPTION
Opening the therapeutic window - between systemic toxicity & lack of efficacy
Happy end - claim to fame & approval
PART VIII: FROM BENCH TO BEDSIDE - THE AFTERMATHS
Think big & dealmaking for growth - global changes in the health-care sector
News & views - quo vadis, biopharmaceuticals?
Small molecules - light at the end of the tunnel or back to the roots?